The histopathological evaluation of drug‐induced liver injury
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Drug‐induced liver injury (DILI) presents unique challenges to the pathologist. It is not only an uncommon reason for liver biopsy, but the pathology of DILI is spread across the entire spectrum of hepatic injury patterns. It is important for the pathologist to suspect DILI when the histological changes are unusual or out of synchronicity with the patient's history. A systematic evaluation approach will yield the most information. It begins with the characterization of the general pattern of injury which, for most cases, will be found in a handful of necroinflammatory and cholestatic patterns. A careful assessment of the severity of injury across the various anatomic compartments will provide information on the probable natural history of the injury. Correlation of liver injury with the patient's medication history and clinical findings will help to narrow the differential diagnosis, particularly when it is recognized that most drugs have a limited range of histological findings and vary in their propensity to cause injury. This review provides an overview of the assessment of the liver biopsy and its use to confirm or exclude particular drugs as contributing to the patient's liver injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The histological features of DILI can mimic any hepatic injury pattern and thus, pose a great challenge for pathologists.29,30,31”
From Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients (2024) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Self-citation
Research works printed but not linked: 58
- Food and Drug Administration, 2000, Withdrawal of troglitazone and cisapride, JAMA, 283, 2228, 10.1001/jama.283.17.2228 · doi:10.1001/jama.283.17.2228
- 10.1016/j.cct.2006.04.005 · DOI
- 10.1053/jhep.2002.34857 · DOI · Paper page
- 10.1001/archinte.1965.03860140008003 · doi:10.1001/archinte.1965.03860140008003
- 10.1002/hep.26709 · DOI · Paper page
- 10.1016/S0016-5085(19)32568-5 · DOI · Paper page
- 10.1042/cs0720263 · DOI · Paper page
- 10.1002/hep.27157 · DOI · Paper page
- 10.1002/hep.23588 · DOI · Paper page
- 10.1002/hep.24481 · DOI · Paper page
- 10.1016/j.cgh.2016.05.043 · DOI · Paper page
- 10.1136/jcp.56.11.850 · doi:10.1136/jcp.56.11.850
- 10.1111/j.1365-2559.1994.tb01321.x · DOI
- 10.1093/ajcp/74.4.442 · DOI
- 10.1016/0016-5085(89)91641-7 · doi:10.1016/0016-5085(89)91641-7
- 10.1055/s-2008-1040724 · DOI · Paper page
- 10.1038/ajg.2015.283 · DOI · Paper page
- Lewis JH, 1988, Methotrexate‐induced chronic liver injury: guidelines for detection and prevention. The ACG Committee on FDA‐related matters. American College of Gastroenterology, Am. J. Gastroenterol., 83, 1337
- 10.1016/S0140-6736(05)74872-8 · DOI
- 10.1016/0046-8177(90)90076-H · DOI · Paper page
- Kleiner DE, 1997, Histopathologic changes associated with fialuridine hepatotoxicity, Mod. Pathol., 10, 192
- 10.1016/S0168-8278(99)80020-8 · DOI · Paper page
- 10.7326/0003-4819-115-4-283 · DOI · Paper page
- Finkle HI, 1999, Hepatic mitochondrial toxicity from nucleoside analog therapy, Arch. Pathol. Lab. Med., 123, 189, 10.5858/1999-123-0189-HMTFNA · DOI
- 10.1002/hep.1840020513 · DOI · Paper page
- 10.1016/0002-9610(67)90308-X · DOI
- 10.1007/s13181-010-0047-0 · DOI
- 10.1016/S0140-6736(83)91629-X · DOI · Paper page
- 10.1111/j.1365-2559.2010.03511.x · DOI · Paper page
- 10.1111/1751-2980.12177 · DOI
- Buffet C, 1988, Three cases of nodular regenerative hyperplasia of the liver following renal transplantation, Nephrol. Dial. Transplant., 3, 327
- 10.1097/01.pas.0000128665.12063.97 · doi:10.1097/01.pas.0000128665.12063.97
- Morse CG, 2015, Nonalcoholic steatohepatitis and hepatic fibrosis in HIV‐1‐monoinfected adults with elevated aminotransferase levels on antiretroviral therapy, Clin. Infect. Dis., 60, 1569, 10.1093/cid/civ101 · DOI
- 10.1097/00000478-200604000-00012 · DOI · Paper page
- 10.1097/00005176-198601000-00008 · doi:10.1097/00005176-198601000-00008
- 10.1002/hep.28323 · DOI · Paper page
- 10.1016/j.cgh.2014.11.036 · DOI · Paper page
- 10.1016/j.gastro.2005.05.006 · DOI · Paper page
- 10.1111/j.1365-2036.2006.03117.x · DOI · Paper page
- 10.1111/his.12449 · doi:10.1111/his.12449
- 10.1016/j.revmed.2012.10.372 · DOI
- 10.1093/rheumatology/kes397 · DOI
- 10.1016/j.cgh.2012.12.025 · DOI · Paper page
- 10.1007/s12185-013-1275-2 · DOI
- 10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U · DOI · Paper page
- 10.1016/j.leukres.2011.01.025 · DOI
- 10.1007/s10620-012-2140-5 · DOI
- 10.1080/10245330600937929 · doi:10.1080/10245330600937929
- 10.1097/MPH.0000000000000337 · doi:10.1097/mph.0000000000000337
- 10.3109/15563650.2012.673624 · DOI
- 10.1200/JCO.2011.41.0332 · DOI
- Irey NS, 1976, Teaching monograph. Tissue reactions to drugs, Am. J. Pathol., 82, 613
- 10.1111/j.1365-2036.2007.03330.x · DOI · Paper page
- 10.1111/j.1478-3231.2006.01377.x · DOI · Paper page
- 10.1111/1751-2980.12184 · doi:10.1111/1751-2980.12184
- 10.1007/978-3-642-00663-0_11 · DOI
- 10.1002/hep.23696 · DOI · Paper page
- 10.1007/s10620-016-4121-6 · DOI
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
“Autoimmune(-Like)” drug and herb induced liver injury: new insights into molecular pathogenesis
Sebode, M., Schulz, L., & Lohse, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091954 · Cited by 47
Wang, C., Deng, Y., Li, P., Zheng, S., Chen, G., Zhou, G., Xu, J., Chen, Y., Wang, Z., Jin, X., et al. (2022) · Hepatology · doi:10.1002/hep.32283 · Cited by 28
Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients
Zhao, X., Wang, Y., Lai, R., Wang, X., Yu, Y., Li, M., Zhao, H., Ma, Z., Li, M., Guo, T., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000235 · Cited by 12
Ipilimumab-associated cholestatic hepatitis: a case report and literature review
Yildirim, S., Deniz, K., Doğan, E., Başkol, M., Gürsoy, Ş., & Özkan, M. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000366 · Cited by 10
Metadata
- Authors
- Kleiner, D. E.
- Affiliations
- Laboratory of Pathology National Cancer Institute Bethesda MD USA
- ORCID
- Kleiner, David E
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2016-12-13
- Volume
- 70
- Issue
- 1
- Pages
- 81-93
- ISSN
- 0309-0167
- 1365-2559
- Cited by
- 52
- References
- 3
- Language
- en
- Funders
- National Institutes of Health
- National Cancer Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.